Danaher stock fails to rise on solid earnings — leading us to question what’s next
Danaher shares dropped on Wednesday because Wall Street was not giving the supplier of tools and equipment to drugmakers and hospitals credit for beating its rosy earnings guidance from earlier this month. Revenue for Danaher’s fourth quarter 2025 rose 4.6% year over year to $6.84 billion, exceeding the LSEG-compiled analyst consensus estimate of nearly $6.81…